Breast cancer drugs should be offered to healthy but high risk women, US panel concludesBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f2499 (Published 18 April 2013) Cite this as: BMJ 2013;346:f2499
- Michael McCarthy
Physicians should offer to prescribe tamoxifen or raloxifene to women who are at a raised risk of breast cancer and have a low risk for the adverse side effects associated with these drugs, say draft recommendations drawn up by a US Preventive Services Task Force panel and released for public comment Tuesday.
The panel’s recommendations apply to asymptomatic women between the ages of 40 and 70 years without a prior diagnosis of breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ.
The panel’s conclusion, which …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial